Wellington Management Group LLP Takes Position in LivaNova PLC (NASDAQ:LIVN)

Wellington Management Group LLP bought a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 192,125 shares of the company's stock, valued at approximately $8,897,000. Wellington Management Group LLP owned about 0.35% of LivaNova as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. PNC Financial Services Group Inc. lifted its holdings in shares of LivaNova by 29.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock worth $292,000 after purchasing an additional 1,424 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of LivaNova by 0.5% in the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock worth $8,240,000 after purchasing an additional 899 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of LivaNova in the 4th quarter worth approximately $2,772,000. Envestnet Asset Management Inc. lifted its holdings in shares of LivaNova by 15.4% in the 4th quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock worth $2,034,000 after purchasing an additional 5,850 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its holdings in shares of LivaNova by 147.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 98,940 shares of the company's stock worth $4,582,000 after purchasing an additional 58,911 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Wall Street Analyst Weigh In

LIVN has been the topic of several recent research reports. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target on the stock in a report on Tuesday, May 20th. Barclays cut their price target on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a report on Thursday, May 8th. The Goldman Sachs Group lowered their target price on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Robert W. Baird raised their target price on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen cut LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $59.29.

LivaNova Stock Performance

LIVN traded up $0.38 during trading hours on Wednesday, hitting $44.48. The company's stock had a trading volume of 470,485 shares, compared to its average volume of 655,467. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $61.40. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.43 billion, a PE ratio of 105.90 and a beta of 0.84. The company has a 50-day simple moving average of $39.21 and a 200 day simple moving average of $44.16.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.